We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Stocks & ETFs Beneficiaries of Coronavirus Vaccine Ramp-Up
Read MoreHide Full Article
The novel coronavirus has infected more than 5.4 million across the globe, at the time writing, perworldometers.com. The death toll has surpassed 346,500 worldwide. The United States alone has crossed 1.6 million cases — the highest number globally. This is followed by Brazil with more than 365,000 cases. No wonder, the race for vaccine development has heated up to bring the world back to normal.
Currently, “there are at least a hundred horses in the race, and we've got some leaders up front,” per Marc Poznansky, the director of the Vaccine and Immunotherapy Center at Massachusetts General Hospital, as quoted on Yahoo Finance. The World Health Organization has recognised some 10 prime candidates for the potential vaccines as these have entered clinical trials. Plus, 114 candidate vaccines are in preclinical evaluation stage.
So, if there is any success, the stocks of the related vaccine-developers will surge ahead. Below we highlight the candidates.
Inside the Prime Candidates
Per WHO, these candidates include mRNA-1273 vaccine by Moderna Inc. (MRNA - Free Report) , potential vaccine ‘ChAdOx1 nCoV-19’ from Oxford University (which is showing limited success as of now) in collaboration with AstraZeneca (AZN - Free Report) and Serum Institute of India, RNA vaccine candidate from the collaboration between U.S.-based Pfizer and German pharmaceutical company BioNtech, and DNA-based vaccine from INOVIO Pharmaceuticals (INO - Free Report) . Also, U.S.-based Novavax’s (NVAX - Free Report) receipt of $388 million of funding from the Coalition for Epidemic Preparedness Innovation (CEPI) deserves mention (read: Novavax Soars on Coronavirus Vaccine Funding: ETFs to Gain).
China – the first epicenterof the virus – understandably got heavily engaged in vaccine formulations. Frontrunners among Chinese candidates are Non-Replicating-Viral-Vector-based vaccine from CanSino Biological Inc./Beijing Institute of Biotechnology, vaccines from the Institute of Medical Biology/ Chinese Academy of Medical Sciences, Wuhan Institute of Biological Products/Sinopharm and Beijing-based Sinovac Biotech’s vaccine candidate PiCoVacc.
Notably, in the United States, Moderna has received $483 million in funding from HHS’s Biomedical Advanced Research and Development Authority (BARDA), and is developing its treatment in collaboration with the National Institute of Allergy and Infectious Diseases, per Yahoo Finance.
Candidates in Pre-Clinical Stage
Various parts of world — be it developed or emerging — have found a place in the list. If we talk about the United States, biotech company Vaxart (VXRT - Free Report) announced positive pre-clinical data for its oral tablet vaccine. Non-Replicating-Viral-Vector candidate from University of Georgia/University of Iowa has shown promise. Epivax/University of Georgia’s S protein candidate is also at this stage.
GlaxoSmithKline plc (GSK - Free Report) is a prominent name here. Its collaboration with Sanofi (SNY) for formulating S protein candidate, its yet another collaboration with University of Queensland/ Dynavax for developing Molecular-clamp-stabilized-Spike-protein vaccine, and the coalition for Innovax/Xiamen University/GSK’s COVID-19 XWG-03 truncated S (spike) proteins are notable.
Stocks & ETFs in Focus
Given the big push for coronavirus vaccine development, biotech and healthcare ETFs are in the sweet spot now.
Notably, Moderna (shares up 36.6% past month) has considerable exposure to Loncar Cancer Immunotherapy ETF (CNCR - Free Report) (with about 12.38% weight), iShares Genomics Immunology and Healthcare ETF (IDNA) (with about 11.8% exposure) and Principal Healthcare Innovators Index ETF (BTEC - Free Report) (5.1% focus). These funds have added in the range of 11% to 15% past month.
Novavax shares have gained 132.5% past month (as of May 22, 2020). The stock has sizable exposure of about 8.1% toInvesco DWA Healthcare Momentum ETF (PTH - Free Report) . PTH was up 15.3% past month against about 5% gains for the S&P 500.
AstraZeneca was up 8% past month and has some decent holding in VanEck Vectors Pharmaceutical ETF (PPH) and CNCR. PPH however underperformed the broader market past month.
Overall, biotech ETFs that enjoyed solid momentum past month are ARK Genomic Revolution Multi-Sector ETF (ARKG - Free Report) (up 23.7%), Virtus LifeSci Biotech Clinical Trials ETF (BBC - Free Report) (up 19.5%), CNCR (up 15.6%), IDNA (up 12.9%) and Global X Genomics & Biotechnology ETFGNOM (up 12%).
Want key ETF info delivered straight to your inbox?
Zacks’ free Fund Newsletter will brief you on top news and analysis, as well as top-performing ETFs, each week. Get it free >>
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Stocks & ETFs Beneficiaries of Coronavirus Vaccine Ramp-Up
The novel coronavirus has infected more than 5.4 million across the globe, at the time writing, perworldometers.com. The death toll has surpassed 346,500 worldwide. The United States alone has crossed 1.6 million cases — the highest number globally. This is followed by Brazil with more than 365,000 cases. No wonder, the race for vaccine development has heated up to bring the world back to normal.
Currently, “there are at least a hundred horses in the race, and we've got some leaders up front,” per Marc Poznansky, the director of the Vaccine and Immunotherapy Center at Massachusetts General Hospital, as quoted on Yahoo Finance. The World Health Organization has recognised some 10 prime candidates for the potential vaccines as these have entered clinical trials. Plus, 114 candidate vaccines are in preclinical evaluation stage.
So, if there is any success, the stocks of the related vaccine-developers will surge ahead. Below we highlight the candidates.
Inside the Prime Candidates
Per WHO, these candidates include mRNA-1273 vaccine by Moderna Inc. (MRNA - Free Report) , potential vaccine ‘ChAdOx1 nCoV-19’ from Oxford University (which is showing limited success as of now) in collaboration with AstraZeneca (AZN - Free Report) and Serum Institute of India, RNA vaccine candidate from the collaboration between U.S.-based Pfizer and German pharmaceutical company BioNtech, and DNA-based vaccine from INOVIO Pharmaceuticals (INO - Free Report) . Also, U.S.-based Novavax’s (NVAX - Free Report) receipt of $388 million of funding from the Coalition for Epidemic Preparedness Innovation (CEPI) deserves mention (read: Novavax Soars on Coronavirus Vaccine Funding: ETFs to Gain).
China – the first epicenterof the virus – understandably got heavily engaged in vaccine formulations. Frontrunners among Chinese candidates are Non-Replicating-Viral-Vector-based vaccine from CanSino Biological Inc./Beijing Institute of Biotechnology, vaccines from the Institute of Medical Biology/ Chinese Academy of Medical Sciences, Wuhan Institute of Biological Products/Sinopharm and Beijing-based Sinovac Biotech’s vaccine candidate PiCoVacc.
Notably, in the United States, Moderna has received $483 million in funding from HHS’s Biomedical Advanced Research and Development Authority (BARDA), and is developing its treatment in collaboration with the National Institute of Allergy and Infectious Diseases, per Yahoo Finance.
Candidates in Pre-Clinical Stage
Various parts of world — be it developed or emerging — have found a place in the list. If we talk about the United States, biotech company Vaxart (VXRT - Free Report) announced positive pre-clinical data for its oral tablet vaccine. Non-Replicating-Viral-Vector candidate from University of Georgia/University of Iowa has shown promise. Epivax/University of Georgia’s S protein candidate is also at this stage.
GlaxoSmithKline plc (GSK - Free Report) is a prominent name here. Its collaboration with Sanofi (SNY) for formulating S protein candidate, its yet another collaboration with University of Queensland/ Dynavax for developing Molecular-clamp-stabilized-Spike-protein vaccine, and the coalition for Innovax/Xiamen University/GSK’s COVID-19 XWG-03 truncated S (spike) proteins are notable.
Stocks & ETFs in Focus
Given the big push for coronavirus vaccine development, biotech and healthcare ETFs are in the sweet spot now.
Notably, Moderna (shares up 36.6% past month) has considerable exposure to Loncar Cancer Immunotherapy ETF (CNCR - Free Report) (with about 12.38% weight), iShares Genomics Immunology and Healthcare ETF (IDNA) (with about 11.8% exposure) and Principal Healthcare Innovators Index ETF (BTEC - Free Report) (5.1% focus). These funds have added in the range of 11% to 15% past month.
Novavax shares have gained 132.5% past month (as of May 22, 2020). The stock has sizable exposure of about 8.1% toInvesco DWA Healthcare Momentum ETF (PTH - Free Report) . PTH was up 15.3% past month against about 5% gains for the S&P 500.
AstraZeneca was up 8% past month and has some decent holding in VanEck Vectors Pharmaceutical ETF (PPH) and CNCR. PPH however underperformed the broader market past month.
Overall, biotech ETFs that enjoyed solid momentum past month are ARK Genomic Revolution Multi-Sector ETF (ARKG - Free Report) (up 23.7%), Virtus LifeSci Biotech Clinical Trials ETF (BBC - Free Report) (up 19.5%), CNCR (up 15.6%), IDNA (up 12.9%) and Global X Genomics & Biotechnology ETF GNOM (up 12%).
Want key ETF info delivered straight to your inbox?
Zacks’ free Fund Newsletter will brief you on top news and analysis, as well as top-performing ETFs, each week. Get it free >>